RAC media coverage, page-1406

Wouldn't even need that, it’s a part of the drug development journey once a company reaches a certain point in their drug’s development roles like this are needed to progress further.

Until now RAC was about to outsource when needed, saving RAC (& us) lots of $ for amount of work needed. Looks like we now need someone full time which is an awesome sign, although I’d been hoping to buy more shares around $1.40 but will see what the market makes of this.

Personal thought that while I am no where near the smartest in the room and hardly understand the science I have taken time to do DD, even took an online course in drug development to wrap my head around drug discovery, drug development & drug commercialisation. So for me seeing this roll encourages me, as do DCB’s current communication indicating we are taking the steps that lead to partnerships.

Let’s see what Tuesday holds. Excellent news from RAC & I encourage all to look closer at why this role is needed now.